Related Experiment Videos
Medical management of mild-to-moderate heart failure before the advent of beta blockers
1Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky College of Medicine, (WTA), Lexington 40536-0284, USA.
Abstract:
Clinical trials of beta blockers in heart failure have generally required that patients be receiving optimal drug therapy before randomization to the study medication. Therefore, because beta blockers are used in addition to conventional drug therapy, review of the standard drug therapy of mild-to-moderate heart failure before the advent of beta blockade is essential to understanding the role of beta blockers in the treatment of heart failure. The conventional medical management of systolic heart failure includes angiotensin-converting enzyme (ACE) inhibitors, which should be used as first-line therapy; diuretics, for the management of body fluid-volume excess; digoxin; and some other vasodilators. These therapies have been evaluated in large-scale, randomized, controlled trials. ACE inhibitors have been shown to significantly attenuate disease progression and improve outcome (ie, morbidity and mortality) in patients with mild-to-moderate systolic heart failure. Controversial or unproven therapies include nonglycoside inotropic agents, angiotensin II receptor antagonists, antiarrhythmic agents, anticoagulants, and calcium channel blockers. The pharmacologic management of diastolic heart failure is largely empirical and is directed at reducing symptoms. Symptoms caused by increased ventricular filling pressures may be treated with diuretics and long-acting nitrates. Some calcium channel blockers and most beta blockers prolong diastolic filling time by slowing heart rate, thereby potentially improving the symptoms of diastolic heart failure. Calcium antagonists, beta blockers, diuretics, and ACE inhibitors may also promote regression of left ventricular hypertrophy and thus improve ventricular compliance, possibly preventing the development of diastolic dysfunction. Because randomized controlled trials of diastolic heart failure are lacking, this review focuses on the conventional management of mild-to-moderate systolic heart failure before the advent of beta blockade.
Insights
Before beta blockers, standard heart failure treatment included ACE inhibitors, diuretics, and digoxin. This review examines conventional systolic heart failure therapies prior to beta-blocker integration.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Beta blockers are typically added to optimal drug therapy in heart failure clinical trials.
- Understanding conventional heart failure management before beta blockers is crucial for assessing their role.
Purpose of the Study:
- To review standard drug therapy for mild-to-moderate systolic heart failure before the introduction of beta blockers.
- To establish a baseline understanding of heart failure treatment paradigms.
Main Methods:
- Literature review focusing on randomized controlled trials of heart failure therapies.
- Analysis of conventional medical management for systolic heart failure.
- Examination of pharmacologic approaches for diastolic heart failure.
Main Results:
- Angiotensin-converting enzyme (ACE) inhibitors are first-line therapy for systolic heart failure, improving outcomes.
- Diuretics manage fluid overload, digoxin aids in treatment, and vasodilators are also used.
- Management of diastolic heart failure is empirical, focusing on symptom relief and potentially improved ventricular compliance with certain agents.
Conclusions:
- Conventional systolic heart failure management relies on ACE inhibitors, diuretics, and digoxin.
- Beta blockers are an addition to, not a replacement for, established therapies.
- Further research is needed for diastolic heart failure, though some agents may improve symptoms and compliance.